{"id":95287,"date":"2025-06-16T11:20:08","date_gmt":"2025-06-16T11:20:08","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/ocugen-inc-announces-u-s-fda-clearance-of-investigational-new-drug-amendment-to-initiate-phase-2-3-pivotal-confirmatory-clinical-trial-of-ocu410st-modifier-gene-therapy-candidate-for-starga\/"},"modified":"2025-06-16T11:20:08","modified_gmt":"2025-06-16T11:20:08","slug":"ocugen-inc-announces-u-s-fda-clearance-of-investigational-new-drug-amendment-to-initiate-phase-2-3-pivotal-confirmatory-clinical-trial-of-ocu410st-modifier-gene-therapy-candidate-for-starga","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/ocugen-inc-announces-u-s-fda-clearance-of-investigational-new-drug-amendment-to-initiate-phase-2-3-pivotal-confirmatory-clinical-trial-of-ocu410st-modifier-gene-therapy-candidate-for-starga\/","title":{"rendered":"Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2\/3 Pivotal Confirmatory Clinical Trial of OCU410ST\u2014Modifier Gene Therapy Candidate for Stargardt Disease"},"content":{"rendered":"<p align=\"left\">MALVERN, Pa., June  16, 2025  (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2\/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (<em>ABCA4-<\/em>associated retinopathies).\u00a0The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of\u00a0<em>ABCA4<\/em>-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.<\/p>\n<p>\u201cWe have had a highly productive and collaborative engagement with the FDA\u2019s Center for Biologics Evaluation and Research (CBER) in establishing the pivotal confirmatory trial for OCU410ST,\u201d said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. \u201cIt\u2019s evident that there is a real sense of urgency by the agency in providing treatment options for patients who currently have nothing available to them. As we initiate the Phase 2\/3 registration trial, we are expediting the clinical development of OCU410ST by two to three years and potentially providing an innovative gene therapy to patients desperate for a treatment option.\u201d<\/p>\n<p>Positive data from the Phase 1 GARDian trial for OCU410ST demonstrated:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">A favorable safety and tolerability profile with no serious adverse events related to OCU410ST, including no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or choroidal neovascularization and no adverse events of special interest<\/li>\n<li style=\"margin-bottom:8pt\">Considerably slower lesion growth\u201448% at 12-month follow up in evaluable treated eyes when compared to untreated eyes<\/li>\n<li style=\"margin-bottom:8pt\">Statistically significant (p=0.031) improvement with clinically meaningful, nearly 2-line gain in visual function (BCVA) at 12-month follow-up in evaluable treated eyes when compared to untreated eyes<\/li>\n<\/ul>\n<p>The Phase 2\/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease. Of these, 34 will receive a one-time subretinal injection of OCU410ST (200 \u03bcL at a concentration of 1.5 \u00d7 10\u00b9\u00b9 vector genomes\/mL) in the eye with poorer visual acuity, while 17 will be assigned to an untreated control group. The primary objective of the trial is to evaluate the reduction in atrophic lesion size. Key secondary endpoints include improvements in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), compared to controls. Data from the one-year follow-up will be used to support the company\u2019s Biologics License Application (BLA).<\/p>\n<p>\u201cThe initiation of this pivotal Phase 2\/3 study represents a significant milestone in our commitment to bringing transformative genetic therapies to individuals affected by Stargardt disease\u2014a progressive and debilitating condition,\u201d said Dr. Huma Qamar, Chief Medical Officer at Ocugen. \u201cThe recent RPDD granted by the FDA for this program further underscores the urgent need for innovative treatment options for children living with Stargardt disease. OCU410ST, developed through our proprietary modifier gene therapy platform, is designed to target the underlying biological mechanisms of the disease.\u201d<\/p>\n<p>Approximately 100,000 patients in U.S. and Europe combined and 1 million patients globally live with Stargardt disease. Stargardt and <em>ABCA4<\/em>-associated retinopathies are genetically complex, involving more than 1,200 known mutations and addressing this condition with traditional gene therapy or gene editing approaches remains highly challenging.<\/p>\n<p>\u201cStargardt disease represents a significant unmet medical need, particularly among children and young adults,\u201d said Lejla Vajzovic, MD, FASRS, Director of the Duke Surgical Vitreoretinal Fellowship Program and Professor of Ophthalmology, Pediatrics, and Biomedical Engineering with Tenure at Duke University Eye Center. \u201cThe Phase 2\/3 study of OCU410ST is thoughtfully designed with scientific rigor and a patient-centered focus to evaluate both structural and functional outcomes. We are optimistic that this approach will move us closer to a meaningful therapeutic solution for affected families.\u201d<\/p>\n<p>The OCU410ST Phase 2\/3 pivotal confirmatory trial represents a major advancement as Ocugen\u2019s second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its strategic goal of filing three BLAs over the next three years.<\/p>\n<p><strong>About OCU410ST<\/strong><br \/>OCU410ST utilizes an AAV delivery platform for the retinal delivery of the\u00a0<em>RORA<\/em>\u00a0(RAR-Related Orphan Receptor A) gene. It represents Ocugen\u2019s modifier gene therapy approach, which is based on Nuclear Hormone Receptor (NHR)\u00a0RORA that regulates pathophysiological pathways linked to Stargardt disease, such as lipofuscin formation, oxidative stress, complement formation, inflammation, and cell survival networks.<\/p>\n<p><strong>About Stargardt Disease<\/strong><br \/>Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss. Stargardt disease is the most common form of inherited macular degeneration. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula.<\/p>\n<p>Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. Some peripheral vision is usually preserved. Stargardt disease typically develops during childhood or adolescence, but the age of onset and rate of progression can vary. The retinal pigment epithelium (RPE), a layer of cells supporting photoreceptors, is also affected in people with Stargardt disease.<\/p>\n<p><strong>About Ocugen, Inc.<\/strong><br \/>Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient\u2019s lives through courageous innovation\u2014forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wvX7FZMu-7vwyMISWYoAMlHQF13-jpU8Fr9SJDJIN7-kI5FIWhZgRtxgdv0TYRqWrozoiU7rnf2FUF8gf0sW7ZsohpFk4I-sPbe1x2SkM8eScNUcr2a95yKmLJ7PyLvVUCMeyk1Q6xjr2TtamMtKSlqZv2LLApn8tMkWA84tiGEDg_KQWZi4DTjQWkA1-BKhQeiQVbd7vNWlrAe00j1gSgZnZQWZh0YW_j9MlgFy3vtN-qCZhe9AIc1exyKliEYr1ripbv74jWbwXEAREZ36K_j7TuwM1bmXGvfcad9PAjNmXGgROoTRQ76GhPRLqf0rYn2vObwXdkuB3ZVjlGRJLk78OhURSWnewCAO91t6yZr0hizBHjVbkjTJoLzPvanuJHxRbzjmYFtheZZgC48YCHxn642nFBnb2Bn8LbZfuo9UqGq33CTuB5H8TxqcGjyRURsV19VhPd5CGBGB7motmvoYR6qAzDG5gORiet69q81viy5ELaf2EmngWv0Q2MZVVFqcne7uIx66XkZQFcPcc7J-S5uKVvIQWsW2g9OScKDCJwTK1da2JCH8gIqlI-De1Hizv29xzSVPR11HnjjXWnx3OGtrlaRFkVdwyQdvJnVGb5dyK2mPwGlHeQowgPwFbRG3teIVvub8PG0UvWgnsFHcFVhYtrUlESEqxdt2X8TA5QJCzCc9Mp2x6m_tyD9G\" rel=\"nofollow\" target=\"_blank\" title=\"www.ocugen.com\">www.ocugen.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gc9mdyrwmkW1x5laES6oFQp48a9wP-5UQghcj-rwXKXllC17pSZOzmGE5Wpho_ERGf3dJlGmByie9xD2dD7cxSSNhM7thCsI3f7M5vfeSY2iuqYWcXzzftVG5OYaE8NHmPn68J13VVmu-FAL6drUQz0JVEopNe3CNmq1Fo3zJEoTbChloAQx2MuaWlvH4VTxwx1QQ_Dv1r3kvO2cTS2DHIxaSPlEVFUtliASEWHPaDFdmTlUGQJG_j7W11zaRaomKRJudRhjScaPG10uX3OZZJDKNna5Nj0ukd9DZf_uHpAnNUdE0Wk3aFp1txcRCrCoXvy5_UjIActRGbwSRrkRmGpsmQQ7jlKstYcb38469casPpLn6BZu-XkU91LH4fhG5g900j3as0DvlMkiwPBwmJDn3B9XkfqBf6J9ypaFwBNxi1xdlufFeVtA5LtbFRBAqEjkxyKYJIScinTW9vK7tmqbx01L5r1jBPPH0KPaHhS6xrsbVw8Hj7Qyx3AAP4dmhIzsj6_Zfx2iOomg4lS3lzb87pKzIRSCRszH43xrFzGG3WD4nCfryPe_SeztB5YU6vVG21TRjR3Nf7yhwrEfxufguBHGwrZP1or538-EKZwxR-2nuONkIWVnXLt-AVX0ziKUYbZQSyECNGKwfQST_MW5kbpxkQl0iHKEBvZ07azMx1jXTztn6AR65w_BjyroOp75v80Fqun_UbU-WAMBL_UAM06UKYPW8zs_s787YV0fpLRpPg2YR4q3rGcfWQ2F\" rel=\"nofollow\" target=\"_blank\" title=\"X\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e3bRoAxt7lJFYjYdKWSP0f4f186vTy3sZPoKvwPenEee2tiFjMXMrYqihY5zpeq5jLR4FwsA2cMglTKB9-ghCBzf5dPmCkzTi4XrdwSIlCuvP24HMcY_CVfKJCQjfj1iJwA9_Ugu0Nd4a8pjYxClMKVyTG6LdTRp-6kZIOLdnfyTLqFsddrnyctU6tL6kZzHIlLiKdkU__Cg71dPprDV3Oub6mDdyJonmKhVzd4B6uvX8i1msoFStUdKh6A84HLl-6dlPg6zuFndrks9fVGq80bCiBQd_T5iU-9jvw-EdjKwSA98cHVt7KwKr3ycF1wY885UNFz4OY-k0ikFDu39JbEQx7TKIgirhf3N2e6XLmaQJcHy0sSl2_Ue-7oSk6I8M9Xayn-y_Sv-f_nyQLIdIH0faHgODQqQlzCCvXBHhU6AmenkL4a7xk81YrshSteEDSoGB9TjZ_Nq6HNsWGc5RN5zX87MVMa6wd9SvbmwYKJFv731uNiShLq1dP1Shx4djjMiPcRiRAegAehLWOc19n37chtCWHbNe-LM_OVxGUeHlMyIeyQ1c6I8QWo6Gd26UJML9-mdawWqAgLC9bxD0Ue7IOUgjiVGJadLkYppaVZ5pSfo86X2UQgb605iSfy9LFO5cLuWB4IxgBDBlDiT5Avcw55JvT-KbXhGnqfgfyugCmH753cAg0l62nj9IUTE\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<p><strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/><em>This<\/em> <em>press<\/em> <em>release<\/em> <em>contains<\/em> <em>forward-looking<\/em> <em>statements<\/em> <em>within<\/em> <em>the<\/em> <em>meaning<\/em> <em>of<\/em> <em>The<\/em> <em>Private<\/em> <em>Securities<\/em> <em>Litigation<\/em> <em>Reform<\/em> <em>Act<\/em> <em>of<\/em> <em>1995,<\/em> <em>including,<\/em> <em>but<\/em> <em>not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines,<\/em> <em>which<\/em> <em>are<\/em> <em>subject<\/em> <em>to<\/em> <em>risks<\/em> <em>and<\/em> <em>uncertainties.<\/em> <em>We<\/em> <em>may,<\/em> <em>in<\/em> <em>some<\/em> <em>cases,<\/em> <em>use<\/em> <em>terms<\/em> <em>such<\/em> <em>as <\/em><em>\u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d <\/em><em>or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including,<\/em> <em>but<\/em> <em>not<\/em> <em>limited<\/em> <em>to,<\/em> <em>the<\/em> <em>risks<\/em> <em>that<\/em> <em>preliminary,<\/em> <em>interim<\/em> <em>and<\/em> <em>top-line<\/em> <em>clinical<\/em> <em>trial<\/em> <em>results<\/em> <em>may<\/em> <em>not<\/em> <em>be<\/em> <em>indicative<\/em> <em>of,<\/em> <em>and<\/em> <em>may<\/em> <em>differ<\/em> <em>from,<\/em> <em>final<\/em> <em>clinical data;<\/em> <em>the ability of OCU410ST to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data;<\/em> <em>that<\/em> <em>unfavorable<\/em> <em>new<\/em> <em>clinical<\/em> <em>trial<\/em> <em>data<\/em> <em>may<\/em> <em>emerge<\/em> <em>in<\/em> <em>ongoing<\/em> <em>clinical<\/em> <em>trials<\/em> <em>or<\/em> <em>through<\/em> <em>further<\/em> <em>analyses<\/em> <em>of<\/em> <em>existing<\/em> <em>clinical<\/em> <em>trial<\/em> <em>data;<\/em> <em>that<\/em> <em>earlier non-clinical<\/em> <em>and<\/em> <em>clinical<\/em> <em>data<\/em> <em>and<\/em> <em>testing<\/em> <em>of<\/em> <em>may<\/em> <em>not<\/em> <em>be<\/em> <em>predictive<\/em> <em>of<\/em> <em>the<\/em> <em>results<\/em> <em>or<\/em> <em>success<\/em> <em>of<\/em> <em>later<\/em> <em>clinical<\/em> <em>trials;<\/em> <em>and<\/em> <em>that<\/em> <em>that<\/em> <em>clinical<\/em> <em>trial<\/em> <em>data<\/em> <em>are subject to differing interpretations and assessments, including by regulatory authorities.<\/em> <em>These<\/em> <em>and<\/em> <em>other<\/em> <em>risks<\/em> <em>and<\/em> <em>uncertainties<\/em> <em>are<\/em> <em>more<\/em> <em>fully described<\/em> <em>in<\/em> <em>our<\/em> <em>periodic<\/em> <em>filings<\/em> <em>with<\/em> <em>the<\/em> <em>Securities<\/em> <em>and<\/em> <em>Exchange<\/em> <em>Commission<\/em> <em>(SEC),<\/em> <em>including<\/em> <em>the<\/em> <em>risk<\/em> <em>factors<\/em> <em>described<\/em> <em>in<\/em> <em>the<\/em> <em>section<\/em> <em>entitled<\/em> <em>\u201cRisk Factors\u201d<\/em> <em>in<\/em> <em>the<\/em> <em>quarterly<\/em> <em>and<\/em> <em>annual<\/em> <em>reports<\/em> <em>that<\/em> <em>we<\/em> <em>file<\/em> <em>with<\/em> <em>the<\/em> <em>SEC.<\/em> <em>Any<\/em> <em>forward-looking<\/em> <em>statements<\/em> <em>that<\/em> <em>we<\/em> <em>make<\/em> <em>in<\/em> <em>this<\/em> <em>press<\/em> <em>release<\/em> <em>speak<\/em> <em>only<\/em> <em>as of<\/em> <em>the<\/em> <em>date<\/em> <em>of<\/em> <em>this<\/em> <em>press<\/em> <em>release.<\/em> <em>Except<\/em> <em>as<\/em> <em>required<\/em> <em>by<\/em> <em>law,<\/em> <em>we<\/em> <em>assume<\/em> <em>no<\/em> <em>obligation<\/em> <em>to<\/em> <em>update<\/em> <em>forward-looking<\/em> <em>statements<\/em> <em>contained<\/em> <em>in<\/em> <em>this<\/em> <em>press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em><\/p>\n<p><strong>Contact:<\/strong><br \/>Tiffany Hamilton<br \/>AVP, Head of Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pYOGNA6wDwmBO28TFj0i8hzjIh4_yAEf2mFtwhIIG9XhIENTWvVbVvj72Iv1jPf_TNSlp87MwPnMsL7l9XLna1wtrDV_rjk08U29qaI8sp2rTibD1ufTExODPpp99pq5HwbOBmf3gOUy0fethl-NJeWSgUpVYF6iy-xGldEzIquKXsMa7NefUEGzCq78hgoz2selcd1-9AOs3u7OcqU5pWXiZ07Jh27DaelyE68V1s3cP3xGsUlIzzcZdpbRYGlo2yRyJhHw7SLy1_T3eb-UGLfnZsBX5bbID0qAEvi0DjOSkD_YYHu6MkkVgbaoFo_e\" rel=\"nofollow\" target=\"_blank\" title=\"Tiffany.Hamilton@ocugen.com\">Tiffany.Hamilton@ocugen.com<\/a><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2\/3 pivotal confirmatory trial of OCU410ST, a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":95288,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/18d074ba-efcd-41fd-94bc-e3bf2cc4069d","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-95287","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/95287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=95287"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/95287\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/95288"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=95287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=95287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=95287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}